― FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 ―― Completed enrollment in 6 mg and 2 mg dose cohorts of the Phase 1b trial of FTX-6058 in SCD; enrollment ongoing in 12 mg dose cohort ――…
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced…
– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the potential to be the first therapy to treat FSHD, the second most common form of muscular…
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint - Supports proof-of-concept that FTX-6058 is a novel oral HbF inducer - FTX-6058 was generally well…
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability, pharmacokinetics, and other pharmacodynamic measures from the ongoing 6 mg dose cohort of…
Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial Live webcast March 24, 2022 at 10:00am ET CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq:…
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced…